Skip to main content Accessibility help
×
Home
Hostname: page-component-564cf476b6-scc96 Total loading time: 0.322 Render date: 2021-06-22T09:21:28.617Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true }

Psychiatric complications of drug treatment of Parkinson's disease

Published online by Cambridge University Press:  18 September 2015

Summary

Drug-induced psychiatric conditions are a common and severe problem in the treatment of patients with Parkinson's disease. Psychotic symptoms are the most frequent reason for nursing home placement of patients with Parkinson's disease. The psychotic symptoms seem to present themselves in a continuum where alterations in dreaming patterns often precede visual hallucinations, which often progress into delusional syndromes and, finally, into confusional organic syndromes. When evaluating a patient on dopaminergic treatment, it is important to inquire systematically about abnormal sleep related phenomena, for these are important clues in the early detection of psychotic symptoms. The pathogenesis of the psychotic symptoms is not yet fully understood but complex adaptations of various neurotransmitter systems seem to be involved. In the treatment of these drug-induced psychotic symptoms, the atypical antipsychotic drug clozapine plays an important role. Drug-induced mania, hypersexuality and anxiety, although less frequent than the psychotic symptoms, also occur as a complication of dopaminergic treatment. Depressive symptoms, although common in Parkinson's disease, are less likely to occur as a side effect of the drug treatment.

Type
Articles
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2001

Access options

Get access to the full version of this content by using one of the access options below.

References

1.Lang, EA. Lozano, AM. Parkinson's Disease. N Engl J Med 1998;339: 11301143.CrossRefGoogle ScholarPubMed
2.Goetz, CG. Stebbins, GT. Risk factors for nursing home placement in advanced Parkinson disease. Neurology 1993:43:22272229.CrossRefGoogle Scholar
3.Factor, SA, Molho, ES, Podskalny, GD, Brown, D. Parkinson's disease: druginduced psychiatric states. Adv Neurol 1993;65:115138.Google Scholar
4.Ballard, C. Holmes, C. McKeith, I. Neill, D, O'Brien, J. Psychiatric morbidity in dementia with Lewy Bodies: A prospective clinical and neuropathological comparative studv with Alzheimer's disease. Am J Psychiatry 1999;156:10391045.Google Scholar
5.Goodwin, FK. Psychiatric side effects of L-Dopa in man. JAMA 1971;218(13):19151920.CrossRefGoogle ScholarPubMed
6.Cummings, JL. Neuropsychiatrie complications of drug treatment of Parkinson's disease. In: Huber, SJ. Cummings, JL (Eds), Parkinson's disease: Neurobehavioral aspects. Oxford. Oxford University Press. 1992. pp 313327.Google Scholar
7.Aarsland, D. Larsen, JP. Cummings, JL. Laake, K. Prevalence and Clinical Correlates of Psychotic Symptoms in Parkison Disease. A Communitv-Based Study. Arch Neurol 1999;56:595601.CrossRefGoogle Scholar
8.Calne, DB. Williams, AC. Neophytides, A. Plotkin, C. Nutt, JG. Teychenne, PF. Longterm treatment of Parkinsonism with bromocriptine. Lancet 1978:1:735738.CrossRefGoogle Scholar
9.Oertel, WH. Quinn, NP. Parkinson's disease:drug therapy. Clin Neurol 1997:6(1):89108.Google ScholarPubMed
10.Chrisp, P. Mammen, GJ. Sorkin, EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs & Aging 1991:1(3):228248.CrossRefGoogle ScholarPubMed
11.Leonard, BE. Fundamentals of Psychopharmacology. London. John Wiley & Sons Ltd. 1997.Google Scholar
12.Flaherty, JA, Bellur, SN. Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J Clin Psychiatry 1981:42:344345.Google Scholar
13.Schwab, RS. England, AC. Poskanzer, DC. Young, RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969:208(7): 11681170.CrossRefGoogle ScholarPubMed
14.Doraiswamy, M. Martin, W. Metz, A. Deveaugh-Geiss, J. Psychosis in Parkinson's disease. Progr Neuro-Psychopharmacol Biol Psychiatry 1995:19:835846.CrossRefGoogle ScholarPubMed
15.Moskovitz, C. Moses, H. Klawans, HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978:135:669674.Google ScholarPubMed
16.Sanchez-Ramos, JR. Ortoll, R. Paulson, GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996:53:12651268.CrossRefGoogle ScholarPubMed
17.Sweet, RD. McDowell, FH. Feigenson, JS. Loranger, AW. Goodell, H. Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Neurology 1976:26:305310.CrossRefGoogle ScholarPubMed
18.Nausieda, PA. Wiener, WJ. Kaplan, LR. Weber, S. Klawans, HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis? Clin Neuropharmacol 1982:5:183194.CrossRefGoogle ScholarPubMed
19.Klawans, HL. Goetz, CG. Nausieda, PA. Wiener, WJ. Levodopa-induced dopamine receptor hypersensitivity. Ann Neurol 1977:2:125129.CrossRefGoogle Scholar
20.Guttman, M. Dopamine receptors in Parkinson's disease. Neurol Clinics 1992:10(2):377386.CrossRefGoogle ScholarPubMed
21.Stahl, SM. Essential Psychopharmacology. Cambridge. Cambridge University Press. 1996.Google Scholar
22.Melamed, E.Zoldan, J. Friedberg, G. Ziv, I. Weizmann, A. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-Dopa Ticrapy. Adv Neurol 1996:69:545550.Google Scholar
23.Godderis, J. Van de Ven, L. Wils, V. Handbook geriatrische psychiatrie. Leuven. Garant. 1992.Google Scholar
24.Jacoby, R. Oppenheimer, C. Psychiatry in the Elderly. Oxford, Oxford University Press, 1997.Google Scholar
25.Olanow, CW. Koller, WC. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology 1998;50(suppl 3):157.CrossRefGoogle ScholarPubMed
26.Juncos, JL. Management of Psychotic Aspects of Parkinson's Disease. J Clin Psychiatry 1999;60(suppl 8):4253.Google ScholarPubMed
27.Gerlach, J. Peacock, L. New antipsychotics: the present status. Int Clin Psychopharmacol 1995:10(Suppl 3):3948.Google ScholarPubMed
28.Cclesia, GG. Barr, AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970:23:193200.CrossRefGoogle Scholar
29.The Parkinson study group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999:340:757763.CrossRefGoogle Scholar
30.Cummings, JLManaging psychosis in patients with Parkinson's disease(ed). N Engl J Med 1999:340:801803.CrossRefGoogle Scholar
31.Rich, SS. Friedmann, JH. Ott, BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995:56:556559.Google ScholarPubMed
32.Wolters, EC. Jansen, ENH. Tuynman-qua, HG, Bergmans, PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996:47:10851087.CrossRefGoogle ScholarPubMed
33.Aarsland, D. Larsen, JP. Lim, NG. iandberg, E. Olanzapine for Psychosis in Patients with Parkinson's Disease with and without Dementia. J Neuropsychiatry Clin Neurosci 1999:11:392394CrossRefGoogle ScholarPubMed
34.Wolters, EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999:52 (suppl 3):S10S13.Google ScholarPubMed
35.Zoldan, J. Friedberg, G. Livneh, M. Melamed, E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995:45:13051308.CrossRefGoogle ScholarPubMed
36.Cummings, JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992:149:443454.Google ScholarPubMed
37.Abrams, R. ECT for Parkinson's disease. Am J Psychiatry 1989:146:13911393.Google ScholarPubMed
38.Lcentjes, AFG. van den Broek, WW. Vreeling, FW. Flonig, A. Elektroconvulsietherapic (ECT) alsbehandelmogclijkheid voor motorische svmptomen van M. Parkinson. Acta Neuropsychutrica 1998:10:2226.Google Scholar
39.Frijns, CJM. Koerselman, GF. Depressie bij de ziekte van Parkinson. Tijdschr Psychiatrie 1992:34:313327.Google Scholar
40.Poewe, W. Luginger, E. Depression in Parkinson's disease: Impediments to recognition and treatment options. Neurology 1999:52 (suppl 3):S2S6.Google ScholarPubMed
41.Celesia, GG. Wanamaker, WM. Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst 1972:33:577583.Google ScholarPubMed
42.Faust, V. Manie 1997. Stuttgart. Enke Verlag. 1997.Google Scholar
43.Uitti, RJ. Tanner, CM. Rajput, AH. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmocol 1989:12:375383.CrossRefGoogle ScholarPubMed
44.Stein, MB. Heuser, IJ. Juncos, JL. Uhde, TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990:147:217220.Google ScholarPubMed
45.Schiffer, RB. Kurlan, R. Rubin, A. Boer, S. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988:145:10201022.Google ScholarPubMed
46.Henderson, R. Kurlan, R. Kersun, JM. Como, P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry 1992:257264.Google ScholarPubMed
47.Riley, DE. Lang, AE. The spectrum of levodopa-related Punctuations in Parkinson's disease. Neurology 1993:43:14591464.CrossRefGoogle Scholar
48.Berrios, GE.Campbell, C. Politynska, BE. Autonomic failure.depression and anxiety in Parkinson's disease. Br J Psychiatry 1995:166:789792.CrossRefGoogle Scholar
49.Maricle, RA. Nutt, JG. Carter, JH. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord 1995:3:329332.CrossRefGoogle Scholar

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Psychiatric complications of drug treatment of Parkinson's disease
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Psychiatric complications of drug treatment of Parkinson's disease
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Psychiatric complications of drug treatment of Parkinson's disease
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *